| scholarly article | Q13442814 |
| P2093 | author name string | Kari B Wisinski | |
| Amelia B Zelnak | |||
| P2860 | cites work | A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab | Q24594725 |
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 | ||
| Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy | Q87177751 | ||
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer | Q27851553 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer | Q27852071 | ||
| Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Q27853001 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | Q33393360 | ||
| A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine | Q33401523 | ||
| A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy | Q33410791 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors | Q37690991 | ||
| Current and emerging targeted therapies for metastatic breast cancer | Q37946797 | ||
| Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer | Q39664583 | ||
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study | Q40340899 | ||
| Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab | Q42848146 | ||
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
| Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer | Q43297306 | ||
| Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study | Q43599415 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer | Q47762909 | ||
| Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. | Q52925550 | ||
| Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. | Q53231530 | ||
| Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. | Q54484711 | ||
| Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. | Q54525297 | ||
| Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study | Q80574611 | ||
| Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer | Q84529291 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2014-07-23 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches? | |
| P478 | volume | 121 |
| Q46835072 | CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. |
| Q37123227 | Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer |
| Q36094096 | Novel therapy for locally advanced triple-negative breast cancer |
| Q50133191 | Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care |
Search more.